These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21524870)

  • 41. [Treatment response evaluation by functional imaging].
    Fournier LS; Cuénod CA; Clément O; Frija G
    Cancer Radiother; 2006 Nov; 10(6-7):484-7. PubMed ID: 16959517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small unilamellar vesicles: a platform technology for molecular imaging of brain tumors.
    Iqbal U; Albaghdadi H; Nieh MP; Tuor UI; Mester Z; Stanimirovic D; Katsaras J; Abulrob A
    Nanotechnology; 2011 May; 22(19):195102. PubMed ID: 21436507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetic resonance imaging and spectroscopy methods for molecular imaging.
    Vande Velde G; Baekelandt V; Dresselaers T; Himmelreich U
    Q J Nucl Med Mol Imaging; 2009 Dec; 53(6):565-85. PubMed ID: 20016450
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiparametric MR Imaging of Breast Cancer.
    Rahbar H; Partridge SC
    Magn Reson Imaging Clin N Am; 2016 Feb; 24(1):223-238. PubMed ID: 26613883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Imaging of Breast Cancer: Role of RGD Peptides.
    Chakravarty R; Chakraborty S; Dash A
    Mini Rev Med Chem; 2015; 15(13):1073-94. PubMed ID: 26349490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Imaging with MRI: Potential Application in Pancreatic Cancer.
    Chen C; Wu CQ; Chen TW; Tang MY; Zhang XM
    Biomed Res Int; 2015; 2015():624074. PubMed ID: 26579537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging.
    White NS; McDonald C; Farid N; Kuperman J; Karow D; Schenker-Ahmed NM; Bartsch H; Rakow-Penner R; Holland D; Shabaik A; Bjørnerud A; Hope T; Hattangadi-Gluth J; Liss M; Parsons JK; Chen CC; Raman S; Margolis D; Reiter RE; Marks L; Kesari S; Mundt AJ; Kane CJ; Carter BS; Bradley WG; Dale AM
    Cancer Res; 2014 Sep; 74(17):4638-52. PubMed ID: 25183788
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical evaluation of female pelvic tumors : Application fields of integrated PET/MRI].
    Grueneisen J; Umutlu L
    Radiologe; 2016 Jul; 56(7):605-11. PubMed ID: 27315240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer.
    Kwock L; Smith JK; Castillo M; Ewend MG; Collichio F; Morris DE; Bouldin TW; Cush S
    Lancet Oncol; 2006 Oct; 7(10):859-68. PubMed ID: 17012048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progress in magnetic resonance imaging of brain tumours.
    Lemort M; Canizares-Perez AC; Van der Stappen A; Kampouridis S
    Curr Opin Oncol; 2007 Nov; 19(6):616-22. PubMed ID: 17906462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional and molecular imaging with MRI: potential applications in paediatric radiology.
    Arthurs OJ; Gallagher FA
    Pediatr Radiol; 2011 Feb; 41(2):185-98. PubMed ID: 20972674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.
    Kim MJ; Su MY; Yu HJ; Chen JH; Kim EK; Moon HJ; Choi JS
    BMC Cancer; 2016 Feb; 16():50. PubMed ID: 26833069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imaging chemical exchange saturation transfer (CEST) effects following tumor-selective acidification using lonidamine.
    McVicar N; Li AX; Meakin SO; Bartha R
    NMR Biomed; 2015 May; 28(5):566-75. PubMed ID: 25808190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical Applications of Magnetic Resonance Imaging in Oncology.
    Reichardt W; von Elverfeldt D
    Recent Results Cancer Res; 2020; 216():405-437. PubMed ID: 32594394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Promise and pitfalls of quantitative imaging in oncology clinical trials.
    Kurland BF; Gerstner ER; Mountz JM; Schwartz LH; Ryan CW; Graham MM; Buatti JM; Fennessy FM; Eikman EA; Kumar V; Forster KM; Wahl RL; Lieberman FS
    Magn Reson Imaging; 2012 Nov; 30(9):1301-12. PubMed ID: 22898682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular imaging of cancer: MR spectroscopy and beyond.
    Pinker K; Stadlbauer A; Bogner W; Gruber S; Helbich TH
    Eur J Radiol; 2012 Mar; 81(3):566-77. PubMed ID: 20554145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening.
    Hadjipanayis CG; Jiang H; Roberts DW; Yang L
    Semin Oncol; 2011 Feb; 38(1):109-18. PubMed ID: 21362519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Advances in Monitoring Cell-Based Therapies with Magnetic Resonance Imaging: Future Perspectives.
    Ngen EJ; Artemov D
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Utility of MRI contrast agents for diagnosis and treatment follow-up in cancer].
    Siauve N; Clément O
    Bull Cancer; 2007 Feb; 94(2):139-46. PubMed ID: 17337383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential use of nanoparticle based contrast agents in MRI: a molecular imaging perspective.
    Oghabian MA; Farahbakhsh NM
    J Biomed Nanotechnol; 2010 Jun; 6(3):203-13. PubMed ID: 21179937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.